Efficacy of ravuconazole in treatment of systemic murine histoplasmosis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 922-924

  Clemons, K V ^a   Martinez, M ^a   Calderon, L ^a   Stevens, D A ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; RAVUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HISTOPLASMOSIS; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; SYSTEMIC DISEASE;

ANIMALS; ANTIFUNGAL AGENTS; COLONY COUNT, MICROBIAL; FEMALE; FLUCONAZOLE; HISTOPLASMOSIS; ITRACONAZOLE; LIVER; MICE; SPLEEN; SURVIVAL; SURVIVAL ANALYSIS; THIAZOLES; TRIAZOLES;

EID: 0036173451     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.922-924.2002     Document Type: Article

References (26)

1. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
2. Histoplasmosis and blastomycosis
3. Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis
4. Therapy of systemic histoplasmosis in immunosuppressed mice with the triazole D0870
5. Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis
6. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
7. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
8. BMS-207147
9. Histoplasmosis and AIDS
10. Activities of sordarins in murine histoplasmosis
11. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis
12. Treatment of histoplasmosis with MK-991 (L-743,872)
13. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
14. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
15. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial
16. Effect of cyclodextrin on the pharmacology of antifungal oral azoles
17. Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis
18. Progressive disseminated histoplasmosis in patients with AIDS
19. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
20. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
21. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole
22. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives
23. Endemic mycoses in AIDS: A clinical review
24. Practice guidelines for the management of patients with histoplasmosis
25. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans